Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marja-Riitta Taskinen

Showing results (141-150 of 230) with videos related to

Pageof 23
Sort By:
Molecular and Cellular Biology|February 3, 2005
Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factorMaxime Nowak, Audrey Helleboid-Chapman, Heidelinde Jakel, et al.
Journal of Lipid Research|September 13, 2008
Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacityShuhei Nakanishi, Riikka Vikstedt, Sanni Söderlund, et al.
European Journal of Human Genetics : EJHG|August 13, 2002
Genetic influences contributing to LDL particle size in familial combined hyperlipidaemiaJuha Vakkilainen, Päivi Pajukanta, Rita M Cantor, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 21, 2012
Transgenic expression and genetic variation of Lmf1 affect LPL activity in mice and humansMaryam Hosseini, Nicole Ehrhardt, Daphna Weissglas-Volkov, et al.
Plos Genetics|June 10, 2010
Use of genome-wide expression data to mine the "Gray Zone" of GWA studies leads to novel candidate obesity genesJussi Naukkarinen, Ida Surakka, Kirsi H Pietiläinen, et al.
Diabetes Care|February 7, 2009
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialMathijs C Bunck, Michaela Diamant, Anja Cornér, et al.
Diabetes, Obesity & Metabolism|January 27, 2021
Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetesMarja-Riitta Taskinen, Elias Björnson, Niina Matikainen, et al.
Diabetes, Obesity & Metabolism|April 12, 2019
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemiaMartin Adiels, Marja-Riitta Taskinen, Elias Björnson, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Genetic variation at the proprotein convertase subtilisin/kexin type 5 gene modulates high-density lipoprotein cholesterol levelsIulia Iatan, Zari Dastani, Ron Do, et al.
Diabetes|June 9, 2009
ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycanAnne Hiukka, Marcus Ståhlman, Camilla Pettersson, et al.
Pageof 23

Showing results (141-150 of 230) with videos related to

Sort By:
Pageof 23
Molecular and Cellular Biology|February 3, 2005
Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factorMaxime Nowak, Audrey Helleboid-Chapman, Heidelinde Jakel, et al.
Journal of Lipid Research|September 13, 2008
Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacityShuhei Nakanishi, Riikka Vikstedt, Sanni Söderlund, et al.
European Journal of Human Genetics : EJHG|August 13, 2002
Genetic influences contributing to LDL particle size in familial combined hyperlipidaemiaJuha Vakkilainen, Päivi Pajukanta, Rita M Cantor, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 21, 2012
Transgenic expression and genetic variation of Lmf1 affect LPL activity in mice and humansMaryam Hosseini, Nicole Ehrhardt, Daphna Weissglas-Volkov, et al.
Plos Genetics|June 10, 2010
Use of genome-wide expression data to mine the "Gray Zone" of GWA studies leads to novel candidate obesity genesJussi Naukkarinen, Ida Surakka, Kirsi H Pietiläinen, et al.
Diabetes Care|February 7, 2009
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialMathijs C Bunck, Michaela Diamant, Anja Cornér, et al.
Diabetes, Obesity & Metabolism|January 27, 2021
Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetesMarja-Riitta Taskinen, Elias Björnson, Niina Matikainen, et al.
Diabetes, Obesity & Metabolism|April 12, 2019
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemiaMartin Adiels, Marja-Riitta Taskinen, Elias Björnson, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Genetic variation at the proprotein convertase subtilisin/kexin type 5 gene modulates high-density lipoprotein cholesterol levelsIulia Iatan, Zari Dastani, Ron Do, et al.
Diabetes|June 9, 2009
ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycanAnne Hiukka, Marcus Ståhlman, Camilla Pettersson, et al.
Pageof 23